Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome.
about
Drug induced exfoliative dermatitis: state of the artPathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and backEvolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.Idiosyncratic adverse drug reactions: current conceptsDrug allergy: causes and desensitizationDrug reaction with Eosinophilia and Systemic Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current conceptsFever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management.Aging of the CD4 T Cell Compartment.Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System.Fluorescently activated cell sorting followed by microarray profiling of helper T cell subtypes from human peripheral blood.Severe cutaneous adverse drug reactions.Association of CD8(+) T lymphocyte repertoire spreading with the severity of DRESS syndrome.Treatment of DIHS/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir--a hypothesisDrug reaction with eosinophilia and systemic symptoms (DRESS) and its relation with autoimmunity in a reference center in Mexico.New aspects of drug-induced hypersensitivity syndrome.Animal models of toxic epidermal necrolysis.T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction.Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome.Crucial Role of Viral Reactivation in the Development of Severe Drug Eruptions: a Comprehensive Review.Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury.Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis.Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.Eosinophilic Drug Allergy.Adverse cutaneous drug eruptions: current understanding.Cephalosporin-Induced Toxic Epidermal Necrolysis Treated with Intravenous Immunoglobulin.The 9th International Congress on Cutaneous Adverse Drug Reactions at the 23rd World Congress of Dermatology in Vancouver, 2015.Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity.Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital.Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis.Multiple drug sensitization syndrome: A distinct phenotype associated with unrecognized Mycoplasma pneumonia infection.Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS).Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.[DRESS syndrome. Rare and potentially lethal allergic reaction to carbamazepine - a case report].Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms.Gene sharing between Epstein-Barr virus and human immune response genes.Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer.Diagnostic evaluation and risk factors for drug allergies in children: from clinical history to skin and challenge tests.Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR).
P2860
Q26739886-40C771F5-122C-4C19-A6BA-E509A7FB7DA7Q26784638-F962522B-5454-4BAC-B3FC-BECA6DCAAAF3Q26800980-39C43DF5-43DB-4C79-9DE7-79644C85735DQ26824391-4140F854-859D-44B9-BF77-EF23488087ADQ27012238-F857B9D5-F51B-4832-9B2C-51611D72B65AQ27030788-20FC5A93-EE33-436D-9439-413DF6FECD35Q27692095-3F7ECA0D-1D29-422A-A29F-AF76A3B20D0DQ30240144-A60E9057-7161-4C8F-8665-16369DC2A67DQ33607668-98FEC3D3-561C-4688-B143-81E59587BC16Q33838853-B4965D98-D958-4562-9199-F7EBB4654A22Q34472843-9FB0634B-ED36-4F9F-B915-DA39C71854CFQ34525532-140EBB31-A748-46CE-AC7E-6BDA17BF5927Q36292362-F29BE26B-7AA0-4BF0-8AAF-D1CD4312020AQ36577565-7304664D-F05E-4D43-B5EE-9F134DBF4A0DQ37644604-B592093D-3E33-48BF-9159-46081B867145Q37845909-114C1D1E-AC80-4892-B82D-483E872594C3Q37845915-7850A6A4-5C13-401A-9C01-1E7616A74F96Q38033651-A1AA9BBB-82B7-4445-BAC7-9AFF34CCF76BQ38122461-4897D342-E51D-4F53-9022-9F9B9BFBFF12Q38204912-7F900881-33AF-492B-80CF-F2460EF9932EQ38260985-738A6E51-BC87-4ACC-A671-B2A4A02AF60CQ38263760-ED1DE798-2190-4D69-A793-7843830EDC97Q38286374-252EEA8A-9B22-4408-9124-BBC1EE36B212Q38501423-02C4BC0E-C12D-465F-9ABC-C3FB1E137436Q38629246-AD555C40-C2F3-4923-B4E0-A0BF2B704C3DQ38654678-3A777B35-94AB-47DE-A0FE-B2DFE41CFCA3Q38707503-2ED07FF3-3AE3-479D-8003-6E7054B28ADCQ38805641-F1F5B91A-50D1-4F48-BEFE-32A72B240862Q39291741-666DDF77-6F16-4D2B-B8AC-F934D0FE3B7FQ39382537-C5E41EE7-0B35-4E3A-A674-924612A6D762Q39604704-41243778-147E-4FD2-A25C-8B28A4C1D290Q40116092-05358812-83B7-4C41-8FBD-8299492E07D5Q40152488-F1C2B8FE-107C-47F9-8D6B-9326141FB559Q40166488-45E8C4B6-7C16-4513-B60A-01BDA035527EQ40244695-71E7FC29-99A7-4319-8B8D-B38C56D7CA6EQ40511175-C54D1CA2-A01E-43B2-8ADC-F21F2F84016FQ40649135-55F5C559-2E6E-4867-89A6-13C97EEAED24Q40836270-4AB35768-268D-4593-BE83-4D3E4F282470Q41141761-4244CE88-C788-4291-842B-D43F6746A45AQ41521210-56DA79F3-EA52-4731-8B48-A95511680C02
P2860
Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Defective regulatory T cells i ...... logical phenotype and outcome.
@en
Defective regulatory T cells i ...... logical phenotype and outcome.
@nl
type
label
Defective regulatory T cells i ...... logical phenotype and outcome.
@en
Defective regulatory T cells i ...... logical phenotype and outcome.
@nl
prefLabel
Defective regulatory T cells i ...... logical phenotype and outcome.
@en
Defective regulatory T cells i ...... logical phenotype and outcome.
@nl
P2093
P356
P1476
Defective regulatory T cells i ...... logical phenotype and outcome.
@en
P2093
Momoko Kimishima
Ryo Takahashi
Tetsuo Shiohara
Yoshiko Mizukawa
Yoshimi Yamazaki
P304
P356
10.4049/JIMMUNOL.0804002
P407
P577
2009-06-01T00:00:00Z